Helixmith Co Ltd
KOSDAQ:084990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Helixmith Co Ltd
Revenue
Helixmith Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
Revenue
₩2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
|
Celltrion Inc
KRX:068270
|
Revenue
₩4.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Revenue
₩651.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Revenue
₩0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Revenue
₩215.9B
|
CAGR 3-Years
96%
|
CAGR 5-Years
38%
|
CAGR 10-Years
47%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Revenue
₩79.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
58%
|
CAGR 10-Years
N/A
|
|
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
See Also
What is Helixmith Co Ltd's Revenue?
Revenue
2.6B
KRW
Based on the financial report for Dec 31, 2025, Helixmith Co Ltd's Revenue amounts to 2.6B KRW.
What is Helixmith Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
-10%
Over the last year, the Revenue growth was -48%. The average annual Revenue growth rates for Helixmith Co Ltd have been -2% over the past three years , -10% over the past five years , and -10% over the past ten years .
